Clinical utility of MANAGE-PD: a cross-sectional study to characterize Parkinson’s disease patients in Türkiye

MANAGE-PD is a clinical decision-support web-based tool that facilitates healthcare professionals in determining patients with Parkinson’s disease who are inadequately controlled on oral medications. This was the first national, non-interventional study aimed to assess the distribution of patients throughout MANAGE-PD categories, and the clinical characteristics, concordance with physician assessment and tool categorization, and usability of the tool MANAGE-PD in Türkiye. Patients were classified into three treatment groups based on symptom control and therapeutic requirements: adequately controlled on current oral therapy (Category 1), inadequately controlled with a recommendation for oral therapy optimization (Category 2) and inadequately controlled with a recommendation for both oral optimization and consideration of device-aided treatment (DAT) (Category 3). The main outcome was the proportion of patients in the MANAGE-PD categories. Secondary outcomes included clinical features within each group, agreement between MANAGE-PD categorization and physician assessment, planned therapy changes, physician-rated acceptability, and completion time. Clinical evaluations included MDS-UPDRS, NMSS for motor and non-motor symptoms, as well as the PDQ-8 for quality of life. The ease of use of the MANAGE-PD tool was assessed by the physicians using Visual Analog Scale. A total of 514 PD patients from 16 sites were included in the study, of whom 217 patients (42.2%) were adequately controlled on current oral treatment (Category 1), 122 patients (23.7%) were classified as having potential for oral therapy optimization (Category 2), and 175 patients (34.0%) were not well controlled and might benefit from DAT (Category 3). The MDS-UPDRS and NMSS scores exhibited an increase from Category 1 to Category 3, indicating an elevated burden of both motor and non-motor symptoms. PDQ-8 scores demonstrated a reduction in quality of life across categories. There was a moderate agreement between physician judgments of patients’ responses to current therapies and MANAGE-PD classification. MANAGE-PD tool was used as a screening tool in identifying PD patients according to their symptom burden and treatment requirements. The good usability and physician acceptance with moderate agreement with clinical judgment in routine clinical settings was indicated. These results show that the tool might be used as a practical screening tool to identify individuals who may need treatment optimization.